© 2004 European Society for Medical Oncology
Original Article |
Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing
1 Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany; 2 Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
* Correspondence to: Dr J. Lorenzo Bermejo, Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. Tel: +49-6221-421805; Fax: +49-6221-421810; Email: j.lorenzo{at}dkfz.de
Background: Population-based data on the risk of cancer in families eligible for BRCA1/2 mutation testing may help to reach a consensus about the association of BRCA1/2 mutations with cancer at sites other than the breast and may reveal new, non-BRCA1/2 related components of the familial clustering of cancer in those families.
Patients and methods: The families of the Swedish Family-Cancer Database with at least three generations (n = 944 723) were classified according to the criteria proposed by the German Consortium for Hereditary Breast and Ovarian Cancer. The cancer incidences in the classified families were compared with the incidences in the general population. The percentages of individuals with cancer in families eligible for BRCA1/2 mutation testing were compared with data in the literature to estimate the proportion of malignancies related to BRCA1/2 mutations.
Results: Families with two breast cancers before the age of 50 years showed increased risk of early onset pancreatic, prostate and ovarian cancers; families with ovarian and breast cancers presented increased incidences for ovarian and ocular cancers; families with two breast cancers, at least one of them under the age of 50 years, showed increased risks of prostate and primary liver cancers. Stomach cancer before age 70 years was twice as frequent in families with breast and ovarian cancers as in the general population. BRCA1/2 mutations probably explain most of the aggregation of ovarian cancer in families with male breast cancer, and in families with at least two breast cancers diagnosed before age 50 years.
Conclusions: The association of BRCA1/2 mutations with ovarian, pancreatic, prostate and stomach cancers was confirmed at a population level. However, the clustering of early pancreatic cancer in families with two breast cancers under age 50 years, the aggregation of ovarian cancer in families with breast and ovarian cancers, and the increased incidence of early onset prostate cancer in families with male breast cancer seem to be due to other effects unrelated to BRCA1/2 mutations.
Key words: BRCA1, BRCA2, mutation testing, clinical criteria
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Pakkanen, E. Pukkala, H. Kainulainen, M. P. Matikainen, P. A. Koivisto, T. L.J. Tammela, and J. Schleutker Incidence of Cancer in Finnish Families with Clinically Aggressive and Nonaggressive Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 3049 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. JAWOROWSKA, C. TARNOWSKA, J. LUBINSKI, P. SERRANO-FERNANDEZ, T. HUZARSKI, B. GORSKI, B. MASOJC, J. JAKUBISZYN, A. KORYTOWSKA, A. KRAM, et al. Clinical Characteristics of Laryngeal Cancer in BRCA-1 Mutation Carriers Anticancer Res, July 1, 2009; 29(7): 2703 - 2705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pensabene, I. Spagnoletti, I. Capuano, C. Condello, S. Pepe, A. Contegiacomo, G. Lombardi, G. Bevilacqua, and M. A. Caligo Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling Ann. Onc., May 1, 2009; 20(5): 874 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Agalliu, R. Gern, S. Leanza, and R. D. Burk Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations Clin. Cancer Res., February 1, 2009; 15(3): 1112 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Ostrander and M. S. Udler The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer Revisited Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1843 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cao, X. Xu, L. L. Cao, R.-H. Wang, X. Coumoul, S. S. Kim, and C.-X. Deng Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach Carcinogenesis, July 1, 2007; 28(7): 1401 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Agalliu, E. M. Kwon, D. Zadory, L. McIntosh, J. Thompson, J. L. Stanford, and E. A. Ostrander Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer Clin. Cancer Res., February 1, 2007; 13(3): 839 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Harlap, O. Paltiel, Y. Friedlander, R. Calderon-Margalit, L. Deutsch, K. R. Kleinhaus, O. Manor, A. I. Neugut, M. Opler, M. C. Perrin, et al. Prostate Cancer in Fathers With Fewer Male Offspring: the Jerusalem Perinatal Study Cohort J Natl Cancer Inst, January 3, 2007; 99(1): 77 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Petersen, M. de Andrade, M. Goggins, R. H. Hruban, M. Bondy, J. F. Korczak, S. Gallinger, H. T. Lynch, S. Syngal, K. G. Rabe, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 704 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Kauff, N. Mitra, M. E. Robson, K. E. Hurley, S. Chuai, D. Goldfrank, E. Wadsworth, J. Lee, T. Cigler, P. I. Borgen, et al. Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families J Natl Cancer Inst, September 21, 2005; 97(18): 1382 - 1384. [Abstract] [Full Text] [PDF]
|
|